Developing Costimulatory Molecules for Immunotherapy of Diseases
- 1st Edition - May 26, 2015
- Latest edition
- Author: Manzoor Ahmad Mir
- Language: English
Developing Costimulatory Molecules for Immunotherapy of Diseases highlights the novel concept of reverse costimulation and how it can be effectively exploited to develop immunothe… Read more
Developing Costimulatory Molecules for Immunotherapy of Diseases
highlights the novel concept of reverse costimulation and how it can be effectively exploited to develop immunotherapy using either humanized antibodies against CD80, CD86, and other costimulatory molecules or CD28 fusinogenic proteins in the treatment of diseases, including allergies, asthma, rheumatoid arthritis, multiple sclerosis, lupus nephritis, severe psoriasis, vulgaris tuberculosis, thopoid, transplantation therapeutic, cancer, and inflammation.The text aims to provide the latest information on the complex roles and interactions within the CD28 and B7 costimulatory families, with the hope that targeting these families will yield new therapies for the treatment of inflammation, autoimmunity, transplantation, cancer, and other infectious diseases.
- Highlights the novel concept of reverse costimulation and how it can be effectively exploited to develop immunotherapy
- Provides the latest information on the complex roles and interactions within the CD28 and B7 costimulatory families
- Targets new therapies for the treatment of inflammation, autoimmunity, transplantation, cancer, and other infectious diseases
Researchers in immunology and infectious diseases, biotechnology, and biochemistry; and health professionals affiliated with pharmaceutical, drug design and immunotherapy and many biotechnology companies
- Dedication
- About the Editor
- Preface
- Acknowledgments
- Chapter 1. Introduction to Costimulation and Costimulatory Molecules
- Introduction
- Costimulatory Molecules
- The B7 Family of Costimulatory Ligands
- ICOS Molecule
- Pathways in the TNFR/TNF Family
- Summary
- References
- Chapter 2. Concept of Reverse Costimulation and Its Role in Diseases
- Introduction
- Concept of Bidirectional Costimulation
- Reverse Costimulation of APCs
- Role of CD80 and CD86 in the Costimulation of B Cells
- Role of Bidirectional Costimulation in the Activation of DCs
- Role of Reverse Costimulation on Macrophages
- Application of Reverse Costimulation in Diseases
- Reverse Costimulation Through CD80 (B7-1)
- Reverse Costimulation Through CTLA-4
- Reverse Signaling Through CD137L/CD137
- References
- Chapter 3. Costimulation Immunotherapy in Infectious Diseases
- Introduction
- Modulation of Costimulatory Molecules by Viruses
- Modulation of Costimulatory Molecules by Bacteria
- Modulation of Costimulatory Molecules by Protozoan Parasites
- Costimulatory Molecules in Therapeutic Vaccination
- Therapeutic Vaccination Using Costimulatory Molecules in HIV
- B7 Costimulatory Molecules in Infectious Diseases
- Costimulatory Molecules in Allergies and Asthma
- Regulation of the Immune Responses to Pathogens Through Costimulatory Molecules
- Role of Coinhibitory Molecules in the Contraction of the Effector Phase of Immune Responses
- Summary
- References
- Chapter 4. Costimulation Immunotherapy in Allergies and Asthma
- Introduction
- Immunology of Allergy and Asthma
- Pathophysiology of Asthma
- Role of Mast Cells in Allergy and Asthma
- Immunotherapy to Allergens
- Costimulation in Allergy and Asthma
- What Makes Costimulatory Molecules a Promising Target in Allergy and Asthma?
- Targeting Costimulatory Molecules for Treatment of Allergen-Induced Airway Inflammation
- Tools for Modulation of Costimulatory Signals
- References
- Chapter 5. Costimulation in Lymphomas and Cancers
- Introduction
- B7 Superfamily of Costimulatory Molecules in Antitumor Immunotherapy
- Fully Humanized Anti-CTLA-4 Antibody in Treatment of Tumors
- TNF:TNFR Superfamily of Costimulatory Molecules in Antitumor Immunity
- Costimulation Immunotherapy and Tumor Tolerance
- Modulation of B7 Pathway to Augment Cancer Immunotherapy
- Bioengineering of T Cells for Cancer Immunotherapy
- Combination of Costimulatory Antibody–Ligand Fusion Proteins for Targeted Cancer Immunotherapy
- Summary and Conclusion
- References
- Chapter 6. T-Cell Costimulation and Its Applications in Diseases
- Introduction to T-Cell Costimulation
- Costimulation Mediated by CD28 Costimulatory Pathway in T Cells
- CD28 Costimulation Enhances T-Cell Survival
- CD28 T-Cell Costimulation in Diseases
- CD28 Costimulation in Primary T-Cell Responses
- Concluding Remarks
- Unanswered Questions
- Promoting T-Cell Function by Modulating Costimulation or Co-inhibition
- Turning on the Stimulators: Antibodies to 4-1BB (CD137), OX40 (134), GITR, and CD40
- Turning Off the Brakes: Antibodies Against CTLA-4 (CD152), PD-1 (CD279), and PD-L1
- Adoptive T-Cell Transfer
- Improving Signaling Capacities—Second- and Third-Generation CARs
- First-Generation CARs
- Second-Generation CARs
- Third-Generation CARs
- CAR T Cells in Clinical Trials
- References
- Index
- Edition: 1
- Latest edition
- Published: May 26, 2015
- Language: English
MM
Manzoor Ahmad Mir
Dr. Manzoor Ahmad Mir holds a Master's in Zoology from HNBG Central University and completed his Ph.D. in Immunology at Jawaharlal Nehru University, New Delhi, and CSIR-Institute of Microbial Technology, Chandigarh. His research focuses on cancer biology, combination therapy in breast cancer, and tuberculosis immunology. Dr. Mir has published over 50 high-impact research papers and book chapters. He has authored more than 15 books with international publishers of repute. He serves on the editorial boards of prestigious journals. He is a member of several scientific organizations, including the American Association of Cancer Research and the Royal British Society. He has received the TARE Fellowship and the SRFP-2019 from the Indian Science Academies. Dr. Mir teaches Cancer Biology and Immunology at the University of Kashmir, where he heads the Department of Bioresources.
Affiliations and expertise
Department of Bioresources, School of Biological Sciences, University of Kashmir, Srinagar, IndiaRead Developing Costimulatory Molecules for Immunotherapy of Diseases on ScienceDirect